

Studies on Vitamin D (Calciferol) and Its Analogues. 15.

24-Nor-1 α ,25-dihydroxyvitamin D₃ and 24-Nor-25-hydroxy-5,6-*trans*-vitamin D₃¹


Antonio Mouriño,^{2a} Patricia Blair,^{2a} Wayne Weeksler,^{2b} R. Lorne Johnson,^{2b} Anthony W. Norman,^{*2b} and William H. Okamura^{*2a}

Departments of Chemistry and Biochemistry, University of California, Riverside, California 92521.

Received November 8, 1977

As part of our continuing structure-function study of the vitamin D₃ (2a) endocrine system and particularly the key metabolites 25-hydroxyvitamin D₃ (2b) and 1 α ,25-dihydroxyvitamin D₃ (2c), the analogues 24-nor-1 α ,25-dihydroxyvitamin D₃ (1b), 24-nor-25-hydroxy-5,6-*trans*-vitamin D₃ (3), and 24a-homo-25-hydroxy-5,6-*trans*-vitamin D₃ (4) were chemically synthesized and biologically evaluated. Analogues 3 and 4 were synthesized in one step by iodine-catalyzed isomerization of 24-nor-25-hydroxyvitamin D₃ (1a) and 24a-homo-25-hydroxyvitamin D₃ (5), respectively. Analogue 1b was synthesized in ten steps (2% overall yield) by the procedure of Barton from 24-nor-25-hydroxycholesterylbenzoate (6). Analogue 1b had readily detectable biological activity in vivo in the rachitic chick while 3 was without detectable activity. This suggests that our previous observations, that not only did analogue 1a have no detectable biological activity but also functioned as an antagonist or antivitamin in the metabolic conversion of 2a to 2b, may be due to 1a's inability to be 1 α -hydroxylated in vivo. Also, quantitation of the relative stimulation of intestinal calcium absorption, in vivo, as well as relative binding in vitro with the chick intestinal cytosol-chromatin receptor system for metabolite 2c suggests the following. For 25-hydroxy analogues both in the 5,6-*cis* series (with a 1 α -hydroxyl) as well as the 5,6-*trans* series (with a pseudo-1 α -hydroxyl), shortening (as in 1b and 3) or lengthening (as in 4) the side chain by one methylene group greatly reduces biological activity.

The analogue 24-nor-25-hydroxyvitamin D₃ (1a),³ which differs from the natural steroidal prohormone 25-hydroxyvitamin D₃ (2b) only in that it lacks a single




side-chain methylene group, was recently biologically evaluated (in vivo, chicks) for its ability to elicit the classic vitamin D mediated responses⁴ of stimulation of intestinal calcium absorption (ICA) and bone calcium mobilization (BCM). Although 1a proved to be devoid of activity in these assays, it was observed to inhibit the normal responses produced by a physiological dose of vitamin D₃ (2a)^{3a} but not that of 2b or 1 α ,25-dihydroxyvitamin D₃ (2c).⁵ This inhibitory effect on 2a represents the first known example of *antivitamin* or antagonist activity in the vitamin D field.⁶ Intriguing questions center around why 24-nor-25-hydroxyvitamin D₃ (1a) is devoid of biological activity and how it functions as an antivitamin. It is the purpose of this paper to describe a pharmacological approach to these questions wherein the synthesis and biological activities of putative metabolites or metabolite equivalents of 1a are described.


In order to establish whether the biological inactivity (ICA and BCM) and antivitamin D₃ activity of 1a are due to its direct biological action or whether it is first metabolized to 24-nor-1 α ,25-dihydroxyvitamin D₃ (1b), just as 2b must be metabolized by the kidney to 2c before it can function physiologically,⁷ it seemed eminently logical to synthesize and biologically evaluate the 5,6-*trans* 3⁸ as well as the 1 α -OH derivative 1b. These goals have been achieved and the results are described below.

Results and Discussion

Synthesis. The iodine-catalyzed isomerization⁹ of 24-nor-25-OH-D₃ (1a)³ to 24-nor-25-OH-5,6-*trans*-D₃ (3)



proceeded as expected. The product was purified chromatographically and characterized spectroscopically. For comparison purposes, the corresponding 24a-homo-25-hydroxy-5,6-*trans*-vitamin D₃ (4) was prepared by anal-



ogous iodine catalysis from the previously reported 24a-homo-5,6-*cis* isomer 5.³ Both 3 and 4 exhibited the UV λ_{\max} 273/ λ_{\min} 233 nm characteristic of 5,6-*trans* vitamins⁹ as well as the unique A-ring fragment (by cleavage across the C₇-C₈ bond) in the mass spectrum characteristic of 5,6-*trans* as well as 5,6-*cis* vitamins.¹⁰ Both 3 and 4 were rigorously purified to TLC homogeneity immediately before biological studies.


Table I.^a Stimulation of Intestinal Calcium Absorption (ICA) and Bone Calcium Mobilization (BCM) by 24-Nor-1 α ,25-(OH) $_2$ -D $_3$

compd	administered dose, nmol	time of assay after dosing, h	BCM ^b (mg of Ca ²⁺ /100 mL of serum \pm SEM)	ICA ^{b,c} (plasma ⁴⁵ Ca ²⁺ , cpm/0.2 mL \pm SEM)	rel enhancement over control (ICA)
control (-D $_3$)			5.0 \pm 0.6	520 \pm 160	(1.0)
D $_3$	3.3	24	6.3 \pm 0.8*	2430 \pm 540*	4.6
1 α ,25-(OH) $_2$ -D $_3$	0.60	12	6.6 \pm 0.8*	1630 \pm 530*	3.1
	3.0	12	6.1 \pm 0.8	1320 \pm 530*	2.5
24-nor-1 α ,25-(OH) $_2$ -D $_3$	0.62	14	4.8 \pm 0.6	420 \pm 160	0.8
	3.1	14	4.4 \pm 0.1	560 \pm 80	1.1
	15.5	14	5.1 \pm 0.1	680 \pm 200	1.3
	62	14	5.0 \pm 0.3	930 \pm 240*	1.8
	310	14	6.5 \pm 0.6	1530 \pm 440*	2.9
	62	14	5.0 \pm 0.3	930 \pm 240*	1.8
	62	18	5.6 \pm 1.0	1470 \pm 700*	2.8
	62	24	5.4 \pm 1.0	770 \pm 280	1.5
	62	36	4.3 \pm 0.9	590 \pm 310	1.1

^a The steroids were administered intraperitoneally in 0.2 mL of 1,2-propanediol-ethanol (1:1). At the indicated time an assay of ICA and BCM was carried out (Experimental Section and ref 4). ^b Each number (ICA and BCM) is the average \pm SEM for groups of six to ten birds all from a single population of birds raised under identical conditions. ^c For the groups marked with an asterisk (*) $p < 0.01$ or with a plus (+) $p < 0.05$ compared with the -D controls (ICA).

With the availability of large quantities of 24-nor-25-hydroxycholesteryl-3 β -benzoate (**6**)¹¹ we used the efficient Barton procedure¹² for synthesizing 1 α ,25-(OH) $_2$ -24-nor-D $_3$ as depicted in Scheme I. The overall yield was 2.0% for the ten steps (average yield, 68%). Vitamin **1b** was proven to be unusually susceptible to conversion to a less polar substance (λ_{\max} 230 nm) of unknown constitution. Thus, it was necessary to purify **1b** by preparative thin-layer chromatography (TLC) immediately before determining its spectral properties or utilizing it for biological assays. It was stored as a dilute solution under argon at dry ice temperature and used within 1 day after purification. The purified **1b** was TLC homogeneous in several systems and its spectral properties (NMR, UV, and MS) were in accord with the assigned structure. Its mass spectrum also reveals the characteristic peaks at m/e 152 and 134, due to the A-ring part by cleavage across the C $_7$ -C $_8$ bond.¹⁰

Biological Assay. Vitamin D $_3$ and related compounds manifest their biological activity in vivo in a number of ways. Two of the more classic physiologic responses include intestinal calcium absorption (ICA) and bone calcium mobilization (BCM). In the former, the calciferol stimulates the translocation of calcium from the mucosal to the serosal side of the intestine. In the latter, the calciferol, by effecting the resorption of calcium from bone, causes an elevation of serum calcium levels. The new analogues (**1b** and **3**) resulting from the synthetic studies described herein were each assayed in vivo in rachitic chicks by the method of Hibberd and Norman.⁴ The assay provides a good measure of the effectiveness of calciferol analogues in mediating the ICA and BCM responses. Shown in Table I is a time-course and dose-response evaluation of the ICA and BCM properties of the newly synthesized 24-nor-1 α ,25-(OH) $_2$ -D $_3$ (**1b**). For comparative purposes a saturating dose of D $_3$ (3.3 nmol) and 1 α ,25-(OH) $_2$ -D $_3$ (0.6 nmol) was given; we have previously established that these represent minimal saturating doses of D $_3$ ¹³ and 1 α ,25-(OH) $_2$ -D $_3$ ^{13c} and that the time course for maximal response is 24–36^{13a} and 12–14 h,¹⁴ respectively. Thus, as is shown in Table I, when a large (62 nmol) dose of 24-nor-1 α ,25-(OH) $_2$ -D $_3$ (**1b**) is given intraperitoneally, the maximum ICA response occurred between 14 and 18 h. This time of maximum response is comparable to the ICA time courses for other 1 α -hydroxylated analogues in the chick, e.g., 1 α -OH-D $_3$ (14 h)¹⁵ and 3-deoxy-1 α ,25-(OH) $_2$ -D $_3$ (15

Scheme I. Synthetic Scheme for 1b^a

^a Reactions: i, KOH-CH $_3$ OH (97%) on **6** (3 β -benzoate of **7**); ii, DDQ (57%); iii, H $_2$ O $_2$ -NaOH (79%); iv, Li/NH $_3$ -THF-NH $_4$ Cl (79%); v, Ac $_2$ O-C $_5$ H $_5$ N (81%); vi, NBS-(C $_6$ H $_5$ COO) $_2$ -hexanes; vii, *s*-collidine (56% from **10b**); viii, $h\nu$, ether; ix, 85–90 $^{\circ}$ C, 2.25 h; x, LiAlH $_4$ -ether (13% from **11**).

h).¹⁶ Having determined that 14 h was an appropriate time for evaluation of 24-nor-1 α ,25-(OH) $_2$ -D $_3$ (**1b**), a dose-response study over the range of 0.62–310 nmol was carried out. At a dose of 310 nmol of this analogue, a maximum stimulation of ICA occurred with only a marginally significant BCM response ($p < 0.1$). These data suggest that 24-nor-1 α ,25-(OH) $_2$ -D $_3$ (**1a**) is relatively more active in the ICA than the BCM system; we have previously reported other examples of differing structural specificity of these two systems.^{4,17} Also an approximate relative dose ratio for maximal ICA response can be estimated for 24-nor-


Table II. Relative Competitive Index (RCI) Values for Analogues of $1\alpha,25\text{-(OH)}_2\text{-D}_3$

compd	RCI ^a
$1\alpha,25\text{-(OH)}_2\text{-D}_3$ (2c)	100
24-nor- $1\alpha,25\text{-(OH)}_2\text{-D}_3$ (1b)	46 ± 4
25-OH-5,6- <i>t</i> - D_3 (12)	0.58 ± 0.19
24-nor-25-OH-5,6- <i>t</i> - D_3 (3)	0.10 ± 0.04
24a-homo-25-OH-5,6- <i>t</i> - D_3 (4)	0.066 ± 0.015

^a The uncertainties are standard deviations. See the Experimental Section for details.

$1\alpha,25\text{-(OH)}_2\text{-D}_3/1\alpha,25\text{-(OH)}_2\text{-D}_3$; this is calculated to be 310/0.6 or 5200/1. Thus the new analogue 1b is only approximately 0.02% as active as $1\alpha,25\text{-(OH)}_2\text{-D}_3$. This emphasizes the critical importance of the normal 8-carbon isooctyl side chain terminated by a tertiary hydroxyl for ICA activity. These results further suggest that our previous reports of no biological activity for 24-nor-25-OH- D_3 (1a) might be due to a lack of further metabolism since, as shown in the current study, the presence of a 1α -hydroxyl group does produce a biologically active molecule.

In separate experiments (data not presented) where a large 163-nmol dose of 24-nor-25-OH-5,6-*trans*- D_3 was given intraperitoneally, there was no stimulation between 5 and 36 h of either ICA or BCM. In the same experiment 25-OH- D_3 , $1\alpha,25\text{-(OH)}_2\text{-D}_3$, and 25-OH-5,6-*trans*- D_3 all stimulated both ICA and BCM. As shown by comparison of the bioassay results given in Table I with the intestinal cytosol-chromatin assay results given in Table II, it is apparent that an analogue with a 24-nor-25-OH side chain, either with (Table I) a 1α -hydroxy group or with a pseudo- 1α -hydroxyl group as in 3, is not efficiently delivered to the intestine or bone. While $1\alpha,25\text{-(OH)}_2\text{-D}_3$ (Table I) and 25-OH-5,6-*trans*- D_3 (12) both were capable

**12**

of significantly stimulating an ICA response, neither 24-nor- $1\alpha,25\text{-(OH)}_2\text{-D}_3$ (discussed above) nor particularly 24-nor-25-OH-5,6-*trans*- D_3 (3), even at a high 163-nmol dose, could marginally stimulate ICA or BCM. It may be concluded that the effective dose ratio for ICA of 24-nor-25-OH-5,6-*trans*- $\text{D}_3/1\alpha,25\text{-(OH)}_2\text{-D}_3$ is less than 163/0.6 or 272/1; i.e., the analogue is less than 0.4% and almost surely less than 0.02% as active as the natural hormone $1\alpha,25\text{-(OH)}_2\text{-D}_3$ when assayed in vivo.

Yet as can be seen (Table II) when 24-nor- $1\alpha,25\text{-(OH)}_2\text{-D}_3$ (1b) is evaluated in the chick intestinal cytosol-chromatin assay, rather than being only 0.02% as effective as $1\alpha,25\text{-(OH)}_2\text{-D}_3$ (Table I), it was about 40% as effective in competing with [^3H]- $1\alpha,25\text{-(OH)}_2\text{-D}_3$. Thus under in vitro analysis, where there is no "delivery problem", this analogue is a quite effective competitor.

Also shown are the RCI values for the 5,6-*trans* derivatives of 25-OH- D_3 (12), 24-nor- and 24a-homo-25- D_3 . As we have reported previously,¹⁸ 5,6-*trans* analogues,

which also have 25-hydroxyl groups, still are not effective competitors with $1\alpha,25\text{-(OH)}_2\text{-D}_3$ even though they have the critical pseudo- 1α -hydroxyl. This is apparently more a reflection of the orientation of the 10,19-methylene in the 5,6-*trans* geometry rather than the absence of a β -hydroxy.¹⁸ By comparison of the RCI values for the standard 25-hydroxyl-containing 8-carbon side chain (RCI = 0.58) with that of a similar side chain which has been shortened (RCI = 0.10) or lengthened (RCI = 0.07) by only one methylene group, it is apparent that these subtle changes effect an 80–90% reduction in an ability to compete. It must be concluded that the chick intestinal cytosol-chromatin receptor system is remarkably sensitive to the length of the 25-hydroxyl containing side chain of its endogenous steroid hormone $1\alpha,25\text{-(OH)}_2\text{-D}_3$ (2c).

In summary, we have established that it is likely that the biological inactivity of 24-nor-25-OH- D_3 (1a) previously reported^{3,19} may be due to its inability to be 1α -hydroxylated since the new steroid 24-nor- $1\alpha,25\text{-(OH)}_2\text{-D}_3$ (1b), whose synthesis is reported in this communication, had detectable ICA activities. This possibility can only be directly evaluated by synthesis of radioactive 24-nor-25-OH- D_3 and analysis of its metabolic fate. Also we have presented new evidence from both in vivo as well as in vitro analysis that the chick vitamin D endocrine system has a remarkably high specificity with regard to its 25-hydroxylated side chain.

Experimental Section

General. All reagents and solvents are analytical reagent grade and were used without further purification unless otherwise indicated. Melting points were taken on a Thomas-Hoover capillary melting point apparatus and are uncorrected. A Varian A-60 instrument was used (unless otherwise indicated) for nuclear magnetic resonance spectra. Deuteriochloroform was used as solvent and tetramethylsilane (Me_4Si , τ 10.00) as internal standard. Ultraviolet (UV) spectra were recorded with a Beckman-DB-GT spectrophotometer and 95% ethanol was used as solvent. Chloroform solutions were used to take infrared (IR) spectra using a Perkin-Elmer 137 spectrophotometer. Dry tetrahydrofuran (THF) or dry ether refers to solvent freshly distilled from lithium aluminum hydride (LiAlH_4). LBPE refers to low-boiling petroleum ether and silica gel refers to 60–200 mesh Baker analyzed reagent. Alumina refers to Woelm activity III material of neutral grade. Microanalyses were performed by Elek Microanalytical Labs, Torrance, Calif. Mass spectra (MS) were obtained using a Finnigan 1015 C mass spectrometer with an ionizer setting of 70 eV/300 μA .

24-Nor-25-hydroxy-5,6-*trans*-vitamin D_3 (3). To a solution of 24-nor-25-hydroxyvitamin D_3 (1a, 5 mg)³ in LBPE (25 mL) was added the dilute iodine stock solution (1 mL of stock diluted to 25 mL with LBPE) (stock solution: freshly prepared, 10 mg of iodine in 100 mL of LBPE). The reaction was allowed to proceed at room temperature for 1 h (nitrogen, diffuse fluorescent room lights). The solution was vigorously washed with 1% aqueous sodium sulfite and then water. After drying (sodium sulfate), the solution was concentrated under vacuum to afford a residue which exhibited λ_{max} 270 nm; TLC (80:20 ether-LBPE) showed the presence of nearly equal amounts of two components (1a/3, R_f 0.24/0.17). Preparative TLC effected separation of pure 3 and recovered 1a contaminated by some 3. The isolated yields (by UV assuming $\epsilon_{273} = 22700$) ranged from 12 to 20% for reactions carried on a 3–5-mg scale and from 6 to 10% on a 1-mg scale. The homogeneity of the product was established by TLC (silica gel G and 10% AgNO_3 -silica gel G using ether, 80:20 ether-LBPE, or 40:60 acetone-benzene). Starting material and the corresponding isotachysterol were absent (TLC, UV). Synthesis, purification, and administration of steroid for biological assays were performed on the same day. Moreover, duplicate bioassays were performed on two or more independently synthesized and purified samples. Synthesis and purification of 3 was also carried out immediately before spectral determination: UV⁹ λ_{max} 273 nm,

λ_{\min} 233 nm; MS m/e (rel intensity) 386 (M, 3), 368 (M - H₂O, 2), 136 (48), 118 (100), and 59 (48).¹⁰

24a-Homo-25-hydroxy-5,6-*trans*-vitamin D₃ (4). The 5,6-*cis* isomer 5 reported earlier³ was isomerized as described in the preceding section except that the isomerization was run at a tenfold greater dilution. One-milligram scale reactions afforded ~20% yields (UV determination assuming $\epsilon_{273} = 22700$)⁹ of TLC homogeneous material (R_f 0.62; 5, R_f 0.58; the corresponding isotachysterol had λ_{\max} 289 nm, R_f 0.51). A freshly synthesized and purified sample exhibited UV⁹ λ_{\max} 273 nm, λ_{\min} 233 nm; MS m/e (rel intensity) 414 (M, 2), 136 (90), 118 (100), and 59 (91).¹⁰

24-Nor-25-hydroxycholesterol (7). The starting material 7 was obtained by saponification of 24-nor-25-hydroxycholesteryl-3 β -benzoate (6).¹¹ Conditions: benzoate 6, 5 g in 10% KOH-methanol (250 mL) and THF (50 mL) for 3 h (room temperature, nitrogen). Workup and crystallization (methanol) afforded 3.84 g (97%, mp 179–180 °C) of pure 7.

24-Nor-25-hydroxy-1,4,6-cholestatrien-3-one (8). A mixture of 7 (2.15 g, 5.52 mmol) and 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ, 4.5 g, 18.8 mmol) in *p*-dioxane (60 mL, freshly distilled from sodium) was refluxed (11 h) under anhydrous conditions. The cooled mixture was filtered and the solid washed with acetone. The combined filtrate and washings were combined and concentrated to a residue which was passed through a short column of alumina (acetone). The residue upon chromatography (dry column alumina, 100 g, 10% acetone-benzene) afforded material which was crystallized (acetone-LBPE). The purified trienone 8 (1.2 g, 57%) exhibited the following: mp 150 °C; NMR τ 2.90 and 3.80 (H₁ and H₂, AB q, $J_{AB} \sim 10.0$ Hz, H₂ further split, 1.5 Hz), 3.8–4.1 (H_{4,6,7}, 3 H, m), 8.80 (C_{19,26,27} 3CH₃, s), and 9.19 (C₁₈CH₃, s); IR ν_{\max} 3570, 3420, 1630, 1600 cm⁻¹; UV λ_{\max} (ϵ) 226 (12000), 260 (9400), 304 nm (12900). Anal. (C₂₆H₃₈O₂) C, H.

24-Nor-25-hydroxy-1 α ,2 α -oxido-4,6-cholestadien-3-one (9). A 25% aqueous sodium hydroxide solution (5 mL) was added to an ice cooled solution of trienone 8 (1.56 g, 4.1 mmol) in *p*-dioxane (120 mL, freshly distilled from sodium). After adding 30% hydrogen peroxide solution (28 mL) and stirring 10 h at room temperature, the reaction mixture was poured at once into ice water (300 mL). Workup (ether; sodium sulfate drying) and crystallization (isopropyl ether-methanol) afforded 1.29 g (79%) of pure 9: mp 148–150 °C; NMR τ 3.88 (H₄, s), 4.3–4.4 (H_{6,7}, m), 6.39 and 6.56 (H_{2,3} and H_{1,5}, AB q, $J_{AB} \sim 4$ Hz; H_{1,5} further split into d, $J \sim 1.5$ Hz), 8.78 (C_{26,27} 2CH₃, s), 8.81 (C₁₉CH₃, s), and 9.20 (C₁₈CH₃, s); IR ν_{\max} 3570, 3510, 1680, 1640 cm⁻¹; UV λ_{\max} 296 nm (ϵ 20200). Anal. (C₂₆H₃₈O₃) C, H.

24-Nor-1 α ,25-dihydroxycholesterol (10a). A solution of lithium (1.67 g, 0.241 mol) in ammonia (~110 mL) and dry THF (84 mL) was prepared under nitrogen at -78 °C. The epoxydienone 9 (1.26 g, 3.16 mmol) in dry THF (25 mL) was added dropwise (1 h) with stirring to the lithium solution at -78 °C. The bath was removed and stirring continued at refluxing ammonia temperature for 3 h. Dry ammonium chloride (14.5 g) was added in small portions over 2.25 h, a saturated aqueous ammonium chloride solution was added over 20 min, and then the ammonia was allowed to evaporate by stirring overnight at room temperature (nitrogen). After adding H₂O-THF to dissolve the precipitated salts, the mixture was extracted thoroughly with chloroform (5 \times 100 mL). After drying and evaporating the solvent, chromatography (silica gel, 35 g, chloroform and 10–20% acetone-benzene) of the residue afforded, after vacuum drying, the triol 10a (1.02 g, 80%) sufficiently pure for the next step: NMR τ 4.4 (H₆, m), ~6.0 (H_{3 β} , br, $W \sim 20$ Hz), 6.15 (H_{1 β} , br, $W \sim 8$ Hz), 8.80 (C_{26,27} 2CH₃, s), 8.96 (C₁₉CH₃, s), and 9.32 (C₁₈CH₃, s). Recrystallization (ethyl acetate-ethanol) afforded a sample with mp 211–212 °C. Anal. (C₂₆H₄₄O₃) C, H.

24-Nor-1 α ,3 β ,25-triacetoxycholest-5-ene (10b). A mixture of triol 10a (534 mg, 1.2 mmol), acetic anhydride (0.2 mL, freshly distilled), and pyridine (6.5 mL, freshly distilled) was refluxed for 40 h under nitrogen. At 13, 26, and 39 h, additional acetic anhydride (0.1 mL each time) was added. After quenching by adding ice pellets and allowing to stand (2 h), the reaction mixture was filtered and then worked up with ether in the usual way. An essentially quantitative yield of vacuum-dried crude triacetate 10b was obtained. Crystallization (2-propanol) afforded 567 mg (81%) of 10b as colorless needles: mp 117–119 °C; NMR τ 4.4

(H₆, br), ~4.9 (H_{1 β} , br, $W \sim 8$ Hz), ~4.9–5.2 (H_{3 α} , br, $W \sim 20$ Hz), 7.94, 7.99, 8.03 (3OAc, s), 8.59 (C_{26,27} 2CH₃, s), 8.90 (C₁₉CH₃, s), and 9.32 (C₁₈CH₃, s); MS m/e (rel intensity) 410 (M - 2HOAc, 6), 118 (100).

24-Nor-1 α ,3 β ,25-triacetoxy-5,7-cholestadiene (11). All operations (under nitrogen) were conducted with minimal exposure to air. To a refluxing solution of 10b (100 mg, 0.19 mmol) and dibenzoyl peroxide (10 mg) in hexanes (4 mL; purified) was added *N*-bromosuccinimide (40 mg, 0.22 mmol) at once. After 20 min at reflux, the mixture was ice cooled and filtered and then the precipitate thoroughly washed with hexanes (4 \times 4 mL). The combined filtrate and washings were stripped (room temperature) and then the resulting residue in xylene (6 mL, purified) was added dropwise (10 min) to refluxing *s*-collidine (6 mL). After 25 min, the cooled mixture was filtered into ether-water and the ether phase was washed with cold 5% hydrochloric acid (until *s*-collidine was absent), saturated sodium bicarbonate, and water. After drying, filtering, and concentrating (high vacuum), the crude residue was chromatographed (10% AgNO₃-silica gel, 35 g, gradient between LBPE and 30% ether-LBPE) to afford TLC pure provitamin triacetate (56 mg, 56% yield) 11. Crystallization (isopropyl ether) afforded 40 mg of material with mp 145–146.5 °C: NMR (Bruker WH-FT-90/D-18, 90 MHz) τ 4.31 and 4.59 (H_{6,7}, AB q, $J_{AB} \sim 5.6$ Hz), ~5.0 (H_{1 β} , $W \sim 8$ Hz, overlapped with H_{3 α} , $W \geq 30$ Hz), 7.92, 7.97, 8.05 (3Ac, s), 8.52 (C_{26,27} 2CH₃, s), 8.99 (C₁₉CH₃, s), and 9.39 (C₁₈CH₃, s); UV λ_{\max} (ϵ) 265 (8400), 274 (11900), 284 (13000), and 296 nm (7600); MS (20 eV) m/e (rel intensity) 528 (M, 2.1), 468 (M - HOAc, 11), 408 (M - 2HOAc, 37), 348 (M - 3HOAc, 63), 155 (100).

24-Nor-1 α ,25-dihydroxyvitamin D₃ (1b). A total of 90 mg of provitamin triacetate 10b in ether (ice cooling, nitrogen purging) was irradiated in six equal batches (15 mg of 10b per 100 mL of ether) by the method previously described.³ The combined photolysis residue was chromatographed (10% AgNO₃-silica gel, 35 g, gradient between 5% ether-LBPE and 30% ether-LBPE). Fractions enriched in provitamin were irradiated again in two batches and the resulting residue was chromatographed (10% AgNO₃-silica gel, 14 g, solvents as above). Fractions from the two chromatographies enriched in λ_{\max} 260 nm, λ_{\min} 236 nm material (previtamin triacetate) were pooled, concentrated, and then heated (85–90 °C, 2.5 h) in isooctane (18 mL, freshly distilled and deoxygenated). Upon concentration, the resulting residue (vacuum dried) was dissolved in dry ether (20 mL) under nitrogen. Lithium aluminum hydride (40 mg) was added under nitrogen to the ether solution and the mixture was refluxed for 1 h. After the addition of ice pellets to quench the reaction, the product was worked up by the usual protocol. The vacuum-dried residual product was chromatographed twice (silica gel, 40 g each time; gradient between 50% ether-LBPE and ether and then between 1–5% methanol-ether). The amount of desired 1b (12.1 mg) was determined from its UV spectrum (λ_{\max} 266 nm, λ_{\min} 230 nm in ether) assuming $\epsilon_{266} 18300$: NMR (Bruker WT-FT-90/D-18, 90 MHz) τ 3.61 (H₆, d, $J \sim 11.5$ Hz), 4.00 (H₇, d, $J \sim 11.5$ Hz), 4.67 (H_{19,27}, br t, $J \sim 1.5$ Hz), 5.00 (H_{19E}, br t, $J \sim 1.3$ Hz), 5.58 (H_{1,5}, br t, $J \sim 6.3$ Hz), 5.78 (H_{3 α} , br m), 8.81 (C_{26,27} 2CH₃, s), and 9.47 (C₁₈CH₃, s); MS (20 eV) m/e (rel intensity) 402 (M, 1), 384 (M - H₂O, 23), 366 (M - 2H₂O, 5), 152 (39), 134 (100).

Vitamin 1b proved to be unusually labile. For this reason, samples were purified (preparative TLC, silica gel G, ethyl acetate) immediately before bioassay or recording spectra. Samples were stored in ether solution under argon at dry ice temperatures for no more than 1 day. The vitamin tended to deteriorate to a less polar material (appeared as a single spot by TLC) with λ_{\max} 230 nm in its UV spectrum.

Bioassay (in Vivo). The analogues 24-nor-25-OH-5,6-*trans*-D₃ (3) and 24-nor-1 α ,25-dihydroxyvitamin D₃ (1b) were assayed in vitamin D deficient (rachitic) chicks for their ability to stimulate intestinal calcium absorption (ICA) and bone calcium mobilization (BCM). White Leghorn cockerels were raised for 4 weeks on a standard rachitogenic, low calcium diet²⁰ without vitamin D supplement. Three days before assay the chicks were placed on a zero calcium diet. The ICA/BCM responses were determined by the procedure of Hibberd and Norman⁴ as follows. The duodenum of lightly ether anesthetized chicks was exposed surgically and 5 μ Ci of ⁴⁵Ca²⁺ + 4 mg of ⁴⁰Ca²⁺ carrier were

introduced in the small intestine. After 30 min the animal was sacrificed by decapitation and the blood collected and allowed to clot. The ICA response was reflected in the amount of measured radioactivity per 0.2-mL aliquot of serum. The BCM response was quantitated directly by atomic absorption spectrometry (Perkin-Elmer Model 303 atomic absorption spectrometer) on appropriately diluted samples of serum (expressed as mg of Ca^{2+} /100 mL of serum). Additional details and the results are given in Table I.

Bioassay (in Vitro). The ability of 24-nor-1 α ,25-dihydroxyvitamin D₃ (1b), 24-nor-25-hydroxy-5,6-*trans*-vitamin D₃ (3), 24a-homo-25-hydroxy-5,6-*trans*-vitamin D₃ (4), and 25-hydroxy-5,6-*trans*-vitamin D₃ (12) to interact with the intestinal receptor system in the chick for 1 α ,25-dihydroxyvitamin D₃ (2c) was assessed, in vitro, by employing a competitive binding assay described previously in detail.¹⁸ This assay is based on the decrease in radioactivity bound to a finite number of chromatin acceptor sites in the presence of increasing concentrations of a nonradioactive competitor and a constant saturating concentration of radioactive 2c which occurs in a reconstituted cytosol-chromatin receptor system. The assay mixture consisted of nonradioactive competitor, tritiated 2c (2×10^{-8} M), and chick intestinal chromatin (375 μ g of DNA) dispersed in a 0.5 mL of cytosol fluid. After incubating these components (30 min, 25 °C), the chromatin was reisolated by centrifugation. The chromatin fraction was washed three times (0.5% Triton X-100 in 0.01 M Tris-HCl, pH 8.5) to remove loosely bound and free steroid. The radioactivity bound to the chromatin was determined to 2% error at a tritium efficiency ranging from 50 to 55% in a Beckman liquid scintillation counter. The results are expressed as the relative competitive index (RCI).^{18b,22} The RCI value is a linear scale where 2c, the natural hormone, is defined as having an RCI of 100. The method of calculation has been previously described in detail.^{18,21,22} See Table II for the results.

Acknowledgment. We are most grateful to Dr. Arnold Hirsch of Diamond Shamrock for a generous gift of 24-nor-25-hydroxycholesteryl- β -benzoate. Dr. Milan Uskoković (Hoffmann-La Roche, Nutley, N.J.) is acknowledged for providing the samples of 2b, 2c, and 12 and Dr. M. Rappoldt (Philips-Duphar, Weesp, The Netherlands) for the sample of crystalline vitamin D₃. Ms. Patricia Roberts and Ms. June Bishop provided valuable contributions in the bioassay studies. The U.S. Public Health Service generously supported this study.^{1a}

References and Notes

- (a) Supported by U.S. Public Health Service Grants AM-16595 and AM-09012. A.M. was partially supported through a Postdoctoral Fellowship from the Spanish Ministry of Education and Science. (b) For paper 14 in this series, see A. Mouriño and W. H. Okamura, *J. Org. Chem.*, **43**, 1653 (1978).
- (a) Department of Chemistry; (b) Department of Biochemistry.
- (a) R. L. Johnson, W. H. Okamura, and A. W. Norman, *Biochem. Biophys. Res. Commun.*, **67**, 797 (1975); (b) R. L. Johnson, S. C. Carey, A. W. Norman, and W. H. Okamura, *J. Med. Chem.*, **20**, 5 (1977).
- By the method of K. Hibberd and A. W. Norman, *Biochem. Pharmacol.*, **18**, 2347 (1969).
- M. L. Hammond, A. Mouriño, P. Blair, W. Weeksler, R. L. Johnson, A. W. Norman, and W. H. Okamura, "Vitamin D: Biochemical, Chemical and Clinical Aspects Related to Calcium Metabolism", Proceedings of the Third Workshop on Vitamin D, A. W. Norman, K. Schaefer, J. W. Coburn, H. F. DeLuca, D. Fraser, H. G. Grigoleit, and D. V. Herrath, Ed., W. de Gruyter Publications, Berlin, 1977, pp 1-4.
- Antihormonal activity is known for many other steroids. For example, see the review article by W. I. P. Mainwaring, *Vitam. Horm. (N.Y.)*, **33**, 223 (1975).
- (a) R. G. Wong, A. W. Norman, C. R. Reddy, and J. W. Coburn, *J. Clin. Invest.*, **51**, 1287 (1972); (b) D. R. Fraser and E. Kodicek, *Nature (London)*, **228**, 764 (1970).
- In 5,6-*trans* vitamins, the β -OH occupies a region topologically equivalent to the uniquely important 1 α -OH of the natural hormone 2c. The β -OH in 5,6-*trans* vitamins is thought to be able to mimic the function of the 1 α -OH in 5,6-*cis* vitamins like 2c. Thus, 5,6-*trans* isomers derived chemically (iodine treatment) from β -OH-5,6-*cis*-vitamins (natural double bond arrangement) are predicted to be able to biologically mimic the putative 1 α , β -(OH)₂-5,6-*cis*-vitamins. For a discussion with literature citations on this subject, see W. H. Okamura, A. W. Norman, and R. M. Wing, *Proc. Natl. Acad. Sci. U.S.A.*, **71**, 4194 (1974).
- A. Verloop, A. L. Koevoet, and E. Havinga, *Recl. Trav. Chim. Pays-Bas*, **74**, 1125 (1955).
- W. H. Okamura, M. L. Hammond, H. J. C. Jacobs, and J. V. Thuijl, *Tetrahedron Lett.*, 4807 (1976).
- Diamond Shamrock Chemical Co. (Franklin Park, Ill.).
- (a) D. H. R. Barton, R. H. Hesse, M. M. Pechet, and E. Rizzardo, *J. Am. Chem. Soc.*, **95**, 2748 (1973); (b) D. H. R. Barton, R. H. Hesse, M. M. Pechet, and E. Rizzardo, *J. Chem. Soc., Chem. Commun.*, 203 (1974).
- (a) A. W. Norman, *Science*, **149**, 184 (1965); (b) T. H. Adams and A. W. Norman, *J. Biol. Chem.*, **245**, 4421 (1970); (c) H. C. Tsai, R. G. Wong, and A. W. Norman, *ibid.*, **247**, 5511 (1972).
- J. F. Myrtle and A. W. Norman, *Science*, **171**, 78 (1971).
- W. H. Okamura, M. N. Mitra, R. M. Wing, and A. W. Norman, *Biochem. Biophys. Res. Commun.*, **60**, 179 (1974).
- W. H. Okamura, M. N. Mitra, D. A. Procsal, and A. W. Norman, *Biochem. Biophys. Res. Commun.*, **65**, 24 (1975).
- (a) A. W. Norman, W. H. Okamura, M. N. Mitra, and R. L. Johnson in "Calcium Metabolism, Bone and Metabolic Diseases", F. Kuhlencordt and H. P. Kruse, Ed., Springer-Verlag, New York, N.Y., 1975, pp 55-67; (b) A. W. Norman, R. L. Johnson, T. W. Osborn, D. A. Procsal, S. C. Carey, M. L. Hammond, M. N. Mitra, M. R. Pirio, A. Rego, R. M. Wing, and W. H. Okamura, *Clin. Endocrinol.*, **5**, 121s (1976); (c) A. W. Norman, R. L. Johnson, R. Corradino, and W. H. Okamura, unpublished results.
- (a) D. A. Procsal, W. H. Okamura, and A. W. Norman, *J. Biol. Chem.*, **250**, 8382 (1975); (b) W. R. Weeksler, W. H. Okamura, and A. W. Norman, *J. Steroid Biochem.*, in press.
- It should be noted that in rats, both 24-nor-25-OH-D₃ (1a) and its 5,6-*trans* isomer 3 elicit ICA and BCM at a single 63-nmol dose (cf. 162-nmol level used in this study). However, a detailed dose-response comparison to 25-OH-D₃ (2b) and 1 α ,25-(OH)₂-D₃ (2c) was not reported [M. F. Holick, M. Garabedian, and H. F. DeLuca, *Biochemistry*, **11**, 2715 (1972)]. In review articles, studies of 24-nor-1 α ,25-(OH)₂-D₃ (1b) have been mentioned. However, details have not been published: H. Schnoes and H. F. DeLuca, *Vitam. Horm. (N.Y.)*, **32**, 385 (1974); H. F. DeLuca and H. Schnoes, *Annu. Rev. Biochem.*, **45**, 631 (1976).
- A. W. Norman and R. J. Wong, *J. Nutr.*, **102**, 1709 (1972).
- D. A. Procsal, H. L. Henry, E. J. Friedlander, and A. W. Norman, *Arch. Biochem. Biophys.*, **179**, 229 (1977).
- S. Liao and T. Liang, *Methods Enzymol.*, **36**, 313 (1975).